Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of selegiline across different psychiatric disorders: A systematic review and meta-analysis of oral and transdermal formulations.
Eur Neuropsychopharmacol
July 2023
Clinical Section of Psychiatry and Psychology - Department of Neuroscience, Reproductive Sciences, and Odontostomatology, University School of Medicine Federico II, Naples, Italy; Laboratory of Molecular and Translational Psychiatry, University School of Medicine Federico II, Naples, Italy.
Selegiline is an irreversible, selective type-B monoamine oxidase inhibitor (MAOI) approved for Parkison's disease-oral and major depressive disorder-transdermal formulation) resulting in non-selective MAOI activity at oral doses≥20 mg/day. The present systematic review and meta-analysis appraises the evidence of different formulations/dosages of selegiline across different psychiatric conditions. We inquired PubMed/MEDLINE/Cochrane-Central/WHO-ICTRP/Clarivate-WebOfScience and the Chinese-Electronic-Journal Database from inception to 10/26/2022 for selegiline trials involving psychiatric patients.
View Article and Find Full Text PDF[Long lasting psychotropic effects after long-term treatment with a hemoderivative].
Fortschr Med
April 1979
Up to now there has been scarcely any publication of precise tests on the duration (lasting effect) of psychotropical effects which have appeared in brain activity after conclusion of a longterm therapy with vasoactive or metabolical substances. In 32 patients with symptoms of arteriosclerosis (average 72 years) a six weeks trial treatment was carried out with the haemoderivat Actihaemyl (6 weeks twice weekly 10 ml i.v.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!